Medical condition
Hepatitis D
Hepatitis D is a medical condition tracked by NovaPharmaNews across 3 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- bulevirtide (HEPCLUDEX) Antiinfectives for systemic use (J05)
- hepatitis b surface antigen (HEPLISAV B) Antiinfectives for systemic use (J07)
- hepatitis b vaccine (recombinant dna) (HBVAXPRO) Antiinfectives for systemic use (J07)
Latest Hepatitis D news
Gilead Secures First Hepatitis D Drug Approval, Sparking Bay Area Competition
Gilead Sciences has achieved a significant milestone with the FDA approval of bulevirtide, the first drug to treat chronic hepatitis D. This landmark decision intensifies the competitive landscape as Bay Area rivals Vir Biotechnology and Mirum Pharmaceuticals advance their own therapies.
FDA Approves Gilead's Hepatitis D Drug: Implications for Pharma
The FDA has cleared Gilead's hepatitis D drug after a four-year wait, marking a significant milestone in hepatitis treatment. This article explores the implications for the pharmaceutical landscape.
FDA Approves First Treatment for Chronic Hepatitis Delta Virus Infection
The FDA has approved the first treatment for Chronic Hepatitis Delta Virus (HDV) infection, marking a significant milestone in liver disease management. This article explores the implications for pharmaceutical companies and investors.